We are live on ! Find out more
BNTX icon

BioNTech

253 hedge funds and large institutions have $4.05B invested in BioNTech in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 81 increasing their positions, 85 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 85

1.36% less ownership

Funds ownership: 16.78%15.42% (-1.4%)

10% less funds holding

Funds holding: 282253 (-29)

17% less capital invested

Capital invested by funds: $4.88B → $4.05B (-$829M)

31% less call options, than puts

Call options by funds: $200M | Put options by funds: $291M

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

51% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 55

Holders
253
Holders Change
-29
Holders Change %
-10.28%
% of All Funds
3.97%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
27
Increased
81
Reduced
85
Closed
55
Calls
$200M
Puts
$291M
Net Calls
-$91.6M
Net Calls Change
+$97.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Axa
26
Axa
France
$21.9M +$2.13M +18,940 +10%
Citadel Advisors
27
Citadel Advisors
Florida
$21M +$21.1M +187,519 +2,803%
Voloridge Investment Management
28
Voloridge Investment Management
Florida
$20.7M +$20.5M +181,832 +1,873%
PAMS
29
Pictet Asset Management (Switzerland)
Switzerland
$19.9M -$7.56M -67,200 -27%
SM
30
Senvest Management
New York
$18.8M +$9.47M +84,200 +93%
Balyasny Asset Management
31
Balyasny Asset Management
Illinois
$16.6M +$17.3M +153,624 New
LP
32
LMR Partners
United Kingdom
$16.3M +$2.33M +20,699 +16%
GF
33
Gates Foundation
Washington
$16M
CS
34
Candriam SCA
Luxembourg
$15.4M -$1.13M -10,080 -7%
Acadian Asset Management
35
Acadian Asset Management
Massachusetts
$15.2M +$3.38M +30,039 +27%
LFDLE
36
La Financiere de L'Echiquier
France
$15M +$4.67M +41,482 +43%
VanEck Associates
37
VanEck Associates
New York
$14.2M -$522K -4,639 -3%
BBA
38
Baader Bank Aktiengesellschaft
Germany
$14M -$13M -115,270 -47%
Legal & General Group
39
Legal & General Group
United Kingdom
$13.9M +$3.01M +26,718 +26%
Bank of America
40
Bank of America
North Carolina
$13.9M -$1.8M -15,988 -11%
State Street
41
State Street
Massachusetts
$13.6M +$157K +1,394 +1%
Robeco Institutional Asset Management
42
Robeco Institutional Asset Management
Netherlands
$13M +$5.11M +45,472 +61%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$12.8M +$6.58M +58,483 +97%
TCM
44
Tekla Capital Management
Massachusetts
$11.2M
UBS Group
45
UBS Group
Switzerland
$11.1M +$1.73M +15,345 +18%
Vontobel Holding
46
Vontobel Holding
Switzerland
$10.2M -$2.74M -24,362 -20%
LSA
47
Leonteq Securities AG
Switzerland
$9.58M +$1.02M +9,088 +11%
American Century Companies
48
American Century Companies
Missouri
$9.38M -$3.89M -34,614 -28%
Geode Capital Management
49
Geode Capital Management
Massachusetts
$9.37M +$282K +2,508 +3%
CS
50
Credit Suisse
Switzerland
$9.05M +$1.75M +15,570 +23%

BNTX Hedge Fund Activity: Q2 2023 in Review

253 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2023, worth a combined $4.05B — down 17% from $4.88B a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of BNTX and 27 opened new positions — a net loss of 28 holders — while 85 trimmed existing stakes and 81 added.

The largest buyer was Citadel Advisors, adding an estimated $21.1M. The largest seller was Envestnet Asset Management, cutting an estimated $108M.

  • 253 institutional investors held BioNTech (BNTX) as of Q2 2023, down from 282 in Q1 2023.
  • Funds reported $4.05B of BioNTech stock for Q2 2023, down 17% quarter-over-quarter.
  • 27 funds opened new BioNTech positions in Q2 2023 and 55 closed out, a net change of -28 holders.
  • The largest BioNTech buyer in Q2 2023 was Citadel Advisors, an estimated $21.1M added.
  • The largest BioNTech seller in Q2 2023 was Envestnet Asset Management, an estimated $108M sold.

Based on aggregated 13F filings for Q2 2023.